Market Place
Sourcing Support
Novocure`s pancreatic cancer meets main goal in late-stage study
03 Dec 2024 //
REUTERS
Zai Lab & Novocure Report Positive Results for Pancreatic Cancer
02 Dec 2024 //
BUSINESSWIRE
Novocure to Participate in Upcoming Investor Conferences
27 Nov 2024 //
BUSINESSWIRE
Novocure Reports Third Quarter 2024 Financial Results
30 Oct 2024 //
BUSINESSWIRE
FDA Approves Novocure’s Optune Lua® For Lung Cancer Treatment
15 Oct 2024 //
BUSINESSWIRE
Novocure to Report Third Quarter 2024 Financial Results
01 Oct 2024 //
BUSINESSWIRE
Novocure To Share GBM Real-World Data On TTFields Therapy At ESMO 2024
09 Sep 2024 //
BUSINESSWIRE
Novocure Reports Second Quarter 2024 Financial Results
25 Jul 2024 //
BUSINESSWIRE
Novocure to Report Second Quarter 2024 Financial Results
01 Jul 2024 //
BUSINESSWIRE
METIS Met Primary Endpoint, Delayed Intracranial Progression, Improved QoL
03 Jun 2024 //
BUSINESSWIRE
Ttfields Glioblastoma Germany Data: Tiger Study Survival Results Reported
23 May 2024 //
BUSINESSWIRE
Novocure Reports First Quarter 2024 Financial Results
02 May 2024 //
BUSINESSWIRE
Novocure Secures New $400M Non-Dilutive Debt Financing
02 May 2024 //
BUSINESSWIRE
Novocure`s METIS Brain Mets NSCLC Data at ASCO 2024
24 Apr 2024 //
BUSINESSWIRE
Novocure Announces Presentations On Tumor Treating Fields at AACR Annual Meeting
05 Apr 2024 //
BUSINESSWIRE
Zai Lab Partner Novocure Announces METIS Ph 3 Trial Met Primary Endpoint
27 Mar 2024 //
BUSINESSWIRE
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
11 Mar 2024 //
BUSINESSWIRE
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
BUSINESSWIRE
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy
18 Jan 2024 //
BUSINESSWIRE
Novocure Announces Last Patient Enrolled in Ph 3 TRIDENT Trial in Glioblastoma
09 Jan 2024 //
BUSINESSWIRE
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues
08 Jan 2024 //
BUSINESSWIRE
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
04 Jan 2024 //
BUSINESSWIRE
Novocure to Participate in 42nd Annual J.P. Morgan Healthcare Conference
27 Dec 2023 //
BUSINESSWIRE
Novocure to cut 200 jobs, sharpen pipeline focus
29 Nov 2023 //
BUSINESSWIRE
Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
21 Nov 2023 //
BUSINESSWIRE
Novocure Announces Presentations on Tumor Treating Fields Therapy
10 Nov 2023 //
BUSINESSWIRE
Novocure Reports Third Quarter 2023 Financial Results
26 Oct 2023 //
BUSINESSWIRE
Novocure to Report Third Quarter 2023 Financial Results
02 Oct 2023 //
BUSINESSWIRE
Novocure Announces The Lancet Oncology Publishes Primary Data Ph3 LUNAR Trial
29 Aug 2023 //
BUSINESSWIRE
Novocure fails PhIII in platinum-resistant ovarian cancer
29 Aug 2023 //
ENDPTS
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial
28 Aug 2023 //
BUSINESSWIRE
Novocure to Participate in Upcoming Investor Conferences
25 Aug 2023 //
BUSINESSWIRE
Novocure Reports Second Quarter 2023 Financial Results
27 Jul 2023 //
BUSINESSWIRE
Novocure to Report Second Quarter 2023 Financial Results
03 Jul 2023 //
BUSINESSWIRE
LUNAR Phase 3 Trial Demonstrates Statistically Significant in Overall Survival
06 Jun 2023 //
BUSINESSWIRE
ASCO: Novocure`s electric fields extend lung cancer survival
06 Jun 2023 //
FIERCE BIOTECH
Novocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
01 Jun 2023 //
BUSINESSWIRE
Novocure Reports First Quarter 2023 Financial Results
04 May 2023 //
BUSINESSWIRE
Novocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial
26 Apr 2023 //
BUSINESSWIRE
Novocure to Report First Quarter 2023 Financial Results
03 Apr 2023 //
BUSINESSWIRE
Kristin Stafford Joins Novocure Board of Directors
29 Mar 2023 //
BUSINESSWIRE
Novocure Announces Last Patient Enrolled in Pivotal METIS Study
01 Mar 2023 //
BUSINESSWIRE
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
23 Feb 2023 //
BUSINESSWIRE
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
BUSINESSWIRE
Novocure Announces Last Patient Enrolled in PANOVA-3 Study of Pancreatic Cancer
15 Feb 2023 //
BUSINESSWIRE
Novocure shakes up C-suite in wake of lung cancer trial win
20 Jan 2023 //
FIERCE BIOTECH
Novocure Announces Organizational Changes to Prepare for Future Growth
19 Jan 2023 //
BUSINESSWIRE
Novocure Announces Full Year and Q4 2022 Net Revenues & Provides Company Update
09 Jan 2023 //
BUSINESSWIRE
Novocure Announces Pivotal LUNAR Study in NSCLC Met Survival Endpoint
05 Jan 2023 //
BUSINESSWIRE
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
23 Nov 2022 //
BUSINESSWIRE
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy
17 Nov 2022 //
BUSINESSWIRE
Novocure Secures CE Mark for New Array
11 Nov 2022 //
BUSINESSWIRE
Novocure Announces publication of Article of Anti-Cancer Mechanisms of Action
20 Oct 2022 //
BUSINESSWIRE
Novocure to Report Third Quarter 2022 Financial Results
03 Oct 2022 //
BUSINESSWIRE
NovoCure Expands Glioblastoma Portfolio in US
23 Sep 2022 //
BIOSPACE
Novocure Announces Creation of U.S. CNS Cancers Franchise
21 Sep 2022 //
BUSINESSWIRE
Novocure to Participate in Upcoming Investor Conferences
31 Aug 2022 //
BUSINESSWIRE
Novocure to Report Second Quarter 2022 Financial Results
01 Jul 2022 //
BUSINESSWIRE
Novocure Enrolls First Patient in KEYNOTE-B36 Together with KEYTRUDA in NSCLC
21 Jun 2022 //
BUSINESSWIRE
